Noxopharm Dividends and Buybacks

Dividend criteria checks 0/6

Noxopharm does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Buyback Yield

Total Shareholder Yield	n/a
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NOX's dividend payments have been increasing.

Dividend Yield vs Market

Noxopharm Dividend Yield vs Market

How does NOX dividend yield compare to the market?
Segment	Dividend Yield
Company (NOX)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.1%
Industry Average (Biotechs)	2.3%
Analyst forecast (NOX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate NOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NOX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NOX has not reported any payouts.

Noxopharm Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

New major risk - Share price stability

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Founder exercised options to buy AU$5.5m worth of stock.

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.69

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies